ErbB3/HER3 overexpression is associated with lung, colon, gastric, and other cancers (Amin et al., 2010) and has been also found to be responsible for resistance to HER2, IGF1R, and EGFR inhibitors in the treatment of several types of cancers (Erjala et al., 2006; Sergina et al., 2007; Desbois-Mouthon et al., 2009; Miller et al., 2009). The gene discussed is ERBB2; the disease is cancer.